| scholarly article | Q13442814 |
| P50 | author | Tom Walsh | Q37380700 |
| Mary-Claire King | Q437741 | ||
| P2093 | author name string | B Fisher | |
| M Lee | |||
| K Hale | |||
| N Wolmark | |||
| L Ford | |||
| National Surgical Adjuvant Breast and Bowel Project | |||
| J Tait | |||
| K Owens | |||
| L Wickerham | |||
| S Wieand | |||
| B K Dunn | |||
| J Costantino | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| tamoxifen | Q412178 | ||
| P304 | page(s) | 2251-2256 | |
| P577 | publication date | 2001-11-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial | |
| P478 | volume | 286 |
| Q57143328 | Q57143328 |
| Q58615760 | A Recurrent Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico |
| Q24803679 | A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment |
| Q36646485 | A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers |
| Q41726822 | Addressing barriers to uptake of breast cancer chemoprevention for patients and providers |
| Q95828290 | Adjuvante systemtherapie des mammakarzinoms |
| Q35585792 | Advances in breast cancer detection and management |
| Q38375045 | Advances in the recognition and management of hereditary cancer |
| Q83917287 | American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction |
| Q91989395 | An Applied Framework in Support of Shared Decision Making about BRCA Genetic Testing |
| Q34305000 | An overview of hereditary breast and ovarian cancer syndrome |
| Q80531975 | Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers |
| Q44461136 | Androgen pathway dysregulation in BRCA1-mutated breast tumors |
| Q36884619 | Anticipating the arrival of low-penetrance genetic testing to primary care medicine |
| Q39242524 | Are we ready for personalized cancer risk management? The view from breast-care providers |
| Q36655092 | Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study |
| Q50952405 | Association between screening family medical history in general medical care and lower burden of cancer worry among women with a close family history of breast cancer. |
| Q37204722 | Australian clinicians and chemoprevention for women at high familial risk for breast cancer |
| Q37801266 | BRCA mutations in the management of breast cancer: the state of the art |
| Q64284450 | BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers |
| Q35546588 | BRCA1 in hormone-responsive cancers |
| Q43943310 | BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients |
| Q26853262 | BRCA1, a 'complex' protein involved in the maintenance of genomic stability |
| Q36426858 | BRCA1/2 associated hereditary breast cancer |
| Q34970470 | BRCA1: mechanisms of inactivation and implications for management of patients |
| Q35152213 | BRCA1: the enigma of tissue-specific tumor development. |
| Q36642745 | Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? |
| Q34497398 | Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention |
| Q40592257 | Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q35812120 | Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ |
| Q37785234 | Breast Cancer Predisposition Syndromes |
| Q33206389 | Breast Cancer in Canadian Women |
| Q36606930 | Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? |
| Q33948726 | Breast cancer before age 40 years |
| Q57134756 | Breast cancer chemoprevention |
| Q27693259 | Breast cancer chemoprevention: old and new approaches |
| Q27692587 | Breast cancer chemoprevention: progress and controversy |
| Q43624639 | Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen? |
| Q35039870 | Breast cancer prevention in women with a BRCA1 or BRCA2 mutation. |
| Q38599973 | Breast cancer prevention with anti-estrogens: review of the current evidence and future directions |
| Q35399596 | Breast cancer risks and risk prediction models |
| Q36573827 | Breast cancer susceptibility testing: past, present and future. |
| Q33809186 | Breast cancer. |
| Q33197133 | Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma |
| Q28602677 | Broad Consent for Research With Biological Samples: Workshop Conclusions |
| Q44487660 | Can breast cancer be chemoprevented in 2003? |
| Q35579930 | Cancer Genetics in Primary Care |
| Q97522312 | Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines |
| Q46060663 | Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting |
| Q34992880 | Cancer risk assessment for the primary care physician |
| Q38564191 | Cancer risk management decision making for BRCA+ women |
| Q48629272 | Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations |
| Q38028798 | Cancer treatment according to BRCA1 and BRCA2 mutations |
| Q27026559 | Challenging and complex decisions in the management of the BRCA mutation carrier |
| Q35998680 | Chemoprevention for Breast Cancer |
| Q28198944 | Chemoprevention for pancreatic cancer |
| Q60936278 | Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment |
| Q57133081 | Chemoprevention of breast cancer |
| Q34585121 | Chemoprevention of breast cancer: implications for postmenopausal women |
| Q36677468 | Chemoprevention of colorectal cancer: two steps forward, one step back? |
| Q36883674 | Chemoprevention strategies 2006. |
| Q35753341 | Chemopreventive drug treatment in subjects with genetic predisposition to cancer: prescriber liability and healthcare disparities |
| Q35687632 | Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review |
| Q35039478 | Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. |
| Q34568554 | Clinical management of BRCA1 and BRCA2 mutation carriers |
| Q82241176 | Clinical management of BRCA1 and BRCA2 mutation carriers |
| Q34167563 | Clinical management of hereditary breast cancer syndromes |
| Q36754871 | Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation |
| Q73666921 | Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy |
| Q37426280 | Cognitive and psychological impact of BRCA genetic counseling in before and after definitive surgery breast cancer patients |
| Q84382410 | Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center |
| Q36738628 | Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers |
| Q57907570 | Counseling and Testing for Inherited Predisposition to Cancer |
| Q33599463 | Current strategies for the prevention of breast cancer |
| Q36203244 | DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. |
| Q75431832 | Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis |
| Q37055268 | Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing |
| Q36492226 | Development and evaluation of a decision aid for BRCA carriers with breast cancer |
| Q39665327 | Differences in physician referral practices and attitudes regarding hereditary breast cancer by clinical practice location |
| Q46053248 | Disclosure pattern and follow-up after the molecular diagnosis of BRCA/CHEK2 mutations |
| Q36110947 | Do Breast Cancer Patients Tested in the Oncology Care Setting Share BRCA Mutation Results with Family Members and Health Care Providers? |
| Q37310845 | Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer? |
| Q89223938 | Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor |
| Q30360376 | Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms |
| Q36614061 | Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. |
| Q35675838 | Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations |
| Q38753738 | Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations |
| Q38825290 | Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds |
| Q56928441 | Epithelial lesions in prophylactic mastectomy specimens from women withBRCA mutations |
| Q50709872 | Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. |
| Q39755420 | Evaluating Markers for Guiding Treatment |
| Q24600238 | Evidence that BRCA1- or BRCA2-associated cancers are not inevitable |
| Q37056948 | Experience with Bilateral Risk-Reducing Mastectomy for an Unaffected BRCA Mutation Carrier |
| Q46971163 | Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. |
| Q46261835 | Factors associated with psychological distress among women of African descent at high risk for BRCA mutations |
| Q50971376 | Family history record and hereditary cancer risk perception according to National Cancer Institute criteria in a Spanish medical oncology service: a retrospective study. |
| Q35051949 | Genetic advances will influence the practice of medicine: examples from cancer research and care of cancer patients |
| Q47884776 | Genetic testing in women with breast cancer: implications for treatment |
| Q35552631 | Genetics and the Management of Women at High Risk for Breast Cancer |
| Q57577428 | Genetics as a tool to improve cancer outcomes: ethics and policy |
| Q35634020 | Genetics for the general internist |
| Q35775223 | Genetics of breast cancer: a topic in evolution |
| Q37242239 | Genomic Biomarkers for Breast Cancer Risk |
| Q59798483 | Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India |
| Q44202163 | HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry |
| Q83525183 | Hereditary breast and ovarian cancer syndrome |
| Q38925408 | Hereditary breast and ovarian cancer: new genes in confined pathways |
| Q36311502 | Hereditary breast and ovarian cancer: review and future perspectives |
| Q36877081 | Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics |
| Q39657506 | Hereditary breast cancer: the era of new susceptibility genes |
| Q34977063 | Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management |
| Q24307401 | Highlight: BRCA1 and BRCA2 proteins in breast cancer |
| Q34953339 | Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies |
| Q37753030 | Hormone prevention strategies for breast, endometrial and ovarian cancers |
| Q33767120 | How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? |
| Q37450153 | Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States |
| Q34467646 | Immunophenotypic predictive profiling of BRCA1-associated breast cancer |
| Q34225990 | Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer |
| Q36953155 | Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome |
| Q38169799 | Influence of sex steroids on inflammation and bone metabolism |
| Q56883656 | Information needs about hereditary breast cancer among women with early-onset breast cancer |
| Q47117168 | Integrating surgery and genetic testing for the modern surgeon. |
| Q42365244 | Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice |
| Q36254990 | Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent? |
| Q30311907 | Knowledge about breast cancer risk factors and hereditary breast cancer among early-onset breast cancer survivors |
| Q34628632 | Letrozole in the treatment of breast cancer |
| Q34114943 | Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy |
| Q35777905 | Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance |
| Q24803332 | Mammographic density is related to stroma and stromal proteoglycan expression |
| Q35678139 | Management issues for elderly patients with breast cancer |
| Q36755872 | Management of breast cancer--part I. |
| Q47399250 | Management of hereditary breast and ovarian cancer |
| Q36925172 | Management of the asymptomatic BRCA mutation carrier |
| Q35182911 | Management of the high-risk patient |
| Q38844679 | Management of women with a hereditary predisposition for breast cancer |
| Q36959824 | Management options after prophylactic surgeries in women with BRCA mutations: a review |
| Q36849977 | Management updates for women with a BRCA1 or BRCA2 mutation |
| Q39270600 | Managing hereditary breast cancer risk in women with and without ovarian cancer |
| Q37991240 | Managing the breast in patients who test positive for hereditary breast cancer |
| Q35761000 | Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers |
| Q33845209 | Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis |
| Q35084790 | Modifiers of risk of hereditary breast and ovarian cancer |
| Q34568559 | Modifiers of risk of hereditary breast cancer |
| Q60946525 | Mutations and Breast Cancer Prevention |
| Q36883664 | New insights into breast cancer genetics and impact on patient management |
| Q35622050 | New insights into estrogen receptor function in human breast cancer |
| Q37845305 | New insights into the prevention and treatment of familial breast cancer |
| Q34386787 | Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial |
| Q31001228 | Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program |
| Q35808372 | Online tool to guide decisions for BRCA1/2 mutation carriers |
| Q37356474 | Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations |
| Q33221678 | Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage |
| Q92281866 | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study |
| Q25257326 | Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer |
| Q37187673 | Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation |
| Q35934073 | Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations |
| Q35659643 | Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts |
| Q34171954 | Personalized Medicine: A Personal View |
| Q28083876 | Personalized assessment and management of women at risk for breast cancer in North America |
| Q33750281 | Personalized medicine: the future is not what it used to be. |
| Q35601587 | Pharmacological prevention of breast cancer: quo vadis? |
| Q50631227 | Physician Risk Assessment Knowledge Regarding BRCA Genetics Testing. |
| Q34727702 | Population screening for cancer-related germline gene mutations |
| Q53655916 | Population-Based Study of Attitudes toward BRCA Genetic Testing among Orthodox Jewish Women. |
| Q44469186 | Predictive genetics in primary care: expectations for the motivational impact of genetic testing affects the importance family physicians place on screening for familial cancer risk |
| Q81149871 | Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population |
| Q24804117 | Prevention of breast cancer by recapitulation of pregnancy hormone levels |
| Q35744037 | Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? |
| Q44487666 | Problems raised by the gynaecologic management of women with BRCA 1 & 2 mutations |
| Q35687696 | Progress in chemoprevention of breast cancer |
| Q37564411 | Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations |
| Q35684391 | Prophylactic and Therapeutic Breast Conservation in BRCA1/2 Mutation Carriers |
| Q39003013 | Prospective multicenter cohort study of estrogen and insulin-like growth factor system in BRCA mutation carriers |
| Q33247995 | Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women |
| Q35930061 | Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence |
| Q51808027 | Psychosocial and ethical issues relating to genetic testing for BRCA1 and BRCA2 breast cancer susceptibility genes. |
| Q44121727 | Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups |
| Q44405225 | Re: Tamoxifen May Be an Effective Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status |
| Q36030264 | Recent developments in critical genes in the molecular biology of breast cancer |
| Q90186243 | Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil |
| Q34652156 | Regulation of progesterone receptor signaling by BRCA1 in mammary cancer |
| Q57116922 | Risk Reduction Strategies in Breast Cancer Prevention |
| Q36824748 | Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors |
| Q36430753 | Risk prediction models for familial breast cancer |
| Q57054864 | Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition |
| Q34974865 | Risk-benefit profiles of women using tamoxifen for chemoprevention |
| Q34749278 | Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study |
| Q33723561 | Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery |
| Q51677736 | Risk-reduction surgery in BRCA mutation carriers in a Spanish population: adherence and results. |
| Q33735001 | Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials |
| Q84706704 | SEOM clinical guidelines for hereditary cancer |
| Q64256332 | Selected medical interventions in women with a deleterious mutation: a population-based study in British Columbia |
| Q34580753 | Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention |
| Q43413003 | Self administered screening for hereditary cancers in conjunction with mammography and ultrasound |
| Q79293502 | Sensitivity of BRCA-1-Related Breast Cancer to Neoadjuvant Chemotherapy: Practical Implications |
| Q35911820 | Should tamoxifen be used in breast cancer prevention? |
| Q41733530 | Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer |
| Q58786293 | Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care |
| Q38676694 | Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature |
| Q24654487 | Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers |
| Q34152993 | Tamoxifen ("Nolvadex"): a review. |
| Q37122297 | Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
| Q34629307 | Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump |
| Q44199927 | Tamoxifen for primary breast cancer prevention in BRCA heterozygotes. |
| Q37600675 | Tamoxifen for women at high risk of breast cancer |
| Q25257858 | Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis |
| Q36218446 | The Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA Carriers |
| Q36695832 | The BOADICEA model of genetic susceptibility to breast and ovarian cancer |
| Q26777891 | The Consequences of a BRCA Mutation in Women |
| Q40912150 | The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition |
| Q47559670 | The Preventive Intervention of Hereditary Breast Cancer |
| Q35564692 | The Use of Gene Tests to Detect Hereditary Predisposition to Chronic Disease: Is Cost-Effectiveness Analysis Relevant? |
| Q33652431 | The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells |
| Q28252084 | The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling |
| Q22252596 | The clinical management of BRCA1 and BRCA2 mutation carriers |
| Q24803014 | The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions |
| Q46301352 | The frequency and outcome of breast cancer risk-reducing surgery in Finnish BRCA1 and BRCA2 mutation carriers |
| Q36149597 | The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications |
| Q35355084 | The pathology of hereditary breast cancer |
| Q33732274 | The prevention of hereditary breast and ovarian cancer: a personal view |
| Q35911530 | The prevention of invasive breast carcinoma |
| Q36317136 | The role of ovarian ablation in the management of breast cancer |
| Q36739586 | The role of prophylactic surgery in cancer prevention |
| Q38703578 | The selective estrogen receptor modulators in breast cancer prevention |
| Q46542512 | The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation |
| Q35251010 | Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair |
| Q33482054 | Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer |
| Q34263162 | Translational advances regarding hereditary breast cancer syndromes |
| Q33820594 | Two decades after BRCA: setting paradigms in personalized cancer care and prevention |
| Q34110074 | Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer |
| Q36389876 | Update on hereditary breast cancer |
| Q37955050 | Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial |
| Q34309892 | Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers |
| Q54775737 | Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation |
| Q77839223 | Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution |
| Q88219476 | Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study |
| Q57008534 | Where There’s a Web, There’s a Way: Commercial Genetic Testing and the Internet |
| Q40284318 | Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses |
| Q90908330 | Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing |
| Q64254541 | Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics |
| Q84232642 | [BRCA1- and BRCA2 mutations: Clinical management of patients with hereditary breast and ovarian cancer] |
Search more.